Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 27, 2019
Daily News
December 27, 2019
- 51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
- Councilor Mori Urges Drug Maker Management to Straighten Up as He Bids Farewell to MHLW
December 27, 2019
- Health Ministry Panel Calls for Simplified Certification Process for Vaccines to Ensure Stable Supplies
December 27, 2019
- Japan Lays Out Action Plan for Whole Genome Analysis; Preliminary Project to Cover 64,000 Cancer Patients, 28,000 for Intractable Diseases
December 27, 2019
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- Generic Use Rate at 76.9% in July-September: JGA
December 27, 2019
- I/O Biotech BrightPath, Osaka Univ. Link Up for R&D of Immunostimulants
December 27, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…